Company intelligence / Profile preview

Fangyuan Huizhong

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Fangyuan Huizhong is a clinical-stage biotechnology company based in Beijing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on high-impact therapeutic areas including oncology, immunology, and the central nervous system. Its lead asset, FY-2001, is a selective TYK2 inhibitor currently undergoing clinical evaluation for the treatment of autoimmune conditions such as psoriasis. By leveraging internal medicinal chemistry expertise, Fangyuan Huizhong aims to develop precision medicines that address significant unmet medical needs in global markets.

Therapeutic areas: OncologyImmunologyDermatology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Fangyuan Huizhong.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fangyuan Huizhong.

Explore the full profile